According to our recent payer coverage analysis for Crohn’s disease treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for Crohn’s disease treatments shows that under the pharmacy benefit, almost 58% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In July 2019, the FDA approved Samsung Bioepis Co., Ltd.’s Hadlima (adalimumab-bwwd) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis. Merck & Co., Inc. will commercialize the drug in the U.S. It is expected to launch after June 30, 2023.